Sarepta Therapeutics,, Inc. Common Stock SRPT
$18.10
-1.74%
at last close
Recent SEC Filings
| Form | Description | Filed | Document |
|---|---|---|---|
| 13F-HR | Institutional holdings | 2026-08-14 | View → |
| 8-K | 8-K | 2026-08-05 | View → |
| 10-Q | 10-Q | 2026-08-05 | View → |
| 4 | 4 | 2026-07-29 | View → |
| 8-K | 8-K | 2026-07-27 | View → |
| 4 | 4 | 2026-06-05 | View → |
| 4 | 4 | 2026-06-05 | View → |
| 4 | 4 | 2026-06-05 | View → |
| 4 | 4 | 2026-06-05 | View → |
| 4 | 4 | 2026-06-05 | View → |
| 4 | 4 | 2026-06-05 | View → |
| 4 | 4 | 2026-06-05 | View → |
| 4 | 4 | 2026-06-05 | View → |
| 8-K | 8-K | 2026-06-04 | View → |
| 13F-HR | Institutional holdings | 2026-05-13 | View → |
| 8-K | 8-K | 2026-05-06 | View → |
| 10-Q | 10-Q | 2026-05-06 | View → |
| DEF 14A | DEF 14A | 2026-04-24 | View → |
| 4 | 4 | 2026-03-13 | View → |
| 4 | 4 | 2026-03-13 | View → |
| 4 | 4 | 2026-03-13 | View → |
| 4 | 4 | 2026-03-13 | View → |
| 4 | 4 | 2026-03-13 | View → |
| 4 | 4 | 2026-03-11 | View → |
| 4 | 4 | 2026-03-11 | View → |
| 4 | 4 | 2026-03-11 | View → |
| 4 | 4 | 2026-03-11 | View → |
| 4 | 4 | 2026-03-03 | View → |
| 4 | 4 | 2026-03-03 | View → |
| 4 | 4 | 2026-03-03 | View → |
| 4 | 4 | 2026-03-03 | View → |
| 4 | 4 | 2026-03-02 | View → |
| 10-K | 10-K | 2026-03-02 | View → |
| 4 | 4 | 2026-02-27 | View → |
| 4 | 4 | 2026-02-27 | View → |
| 8-K | 8-K | 2026-02-25 | View → |
| 8-K | 8-K | 2026-02-25 | View → |
| 13F-HR | Institutional holdings | 2026-02-13 | View → |
| 4 | 4 | 2026-01-29 | View → |
| 4 | 4 | 2026-01-29 | View → |
Filings are sourced directly from the SEC's EDGAR system. Annual reports (10-K) and quarterly reports (10-Q) carry the full financial statements; 8-K filings disclose material events between reports; Form 4 filings record insider purchases and sales.
Key Stats
- Last Close
- $18.10
- Market Cap
- $1.94 billion
- 52-Week Range
- $10.41 – $25.32
- Average Volume
- 3.07 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.